Drug Profile
Research programme: small molecule neurological disease therapeutics
Latest Information Update: 30 Jun 2017
Price :
$50
*
At a glance
- Originator MRC Technology
- Developer Genentech
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 15 Jun 2017 MRC Technology is now called LifeArc
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA
- 12 Jul 2010 Preclinical trials in Neurological disorders in USA (unspecified route)